#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Body unavailable. Use the original source.
#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.